This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doolittle, N. D. Articles by Neuwelt, E. A. Search for Related Content PubMed PubMed Citation Articles by Doolittle, N. D. Articles by Neuwelt, E. A.

Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors¹

Departments of Neurology [N. D. D., L. L. M., R. M. T., C. L., E. A. N.], Pharmacology [R. E. B., J. S. B.], Otolaryngology [R. E. B.], Medicine [M. C. H.], Divisions of Medical Informatics and Outcomes Research [D. F. K.], Hematology and Medical Oncology [M. C. H.], Oregon Health Sciences University, and Research Service [E. A. N.], and Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research [J. A. H.], Veterans Affairs Medical Center [M. C. H., J. A. H., E. A. N.], Portland, Oregon 97201

Carboplatin is effective in the treatment of malignant brain tumors. However, when administered in conjunction with osmotic opening of the blood-brain barrier (BBB), carboplatin is ototoxic. The purpose of this study was to determine whether delayed administration of sodium thiosulfate (STS), given after BBB closure, provided protection against carboplatin ototoxicity. Patients underwent monthly treatment with intra-arterial carboplatin (200 mg/m²/day x 2) in conjunction with osmotic opening of the BBB, for up to 1 year. Audiological assessment was conducted at baseline and within 24 h before each monthly treatment. STS was administered i.v. as one (20 g/m²) or two (20 g/m² and 16 g/m²) 15-min doses, depending on baseline hearing status. The initial group received the first STS dose 2 h (or 2 and 6 h) after carboplatin (STS2) and a subsequent group received STS 4 h (or 4 and 8 h) after carboplatin (STS4). Audiological data were compared with a historical comparison group (HCG) treated with carboplatin without STS. Spearman correlation coefficients comparing STS 2 (n = 24), STS4 (n = 17), and HCG (n = 19) indicated significantly lower rates of ototoxicity with increased delay in STS (P = 0.0006). On the basis of the analysis of hearing levels, there were significant differences among the two STS groups and HCG at 8000 Hz (P = 0.0010) and at 4000 Hz (P = 0.0075). The log-rank test for time to ototoxicity indicated a significant difference between STS4 and HCG (P = 0.0018). Delayed STS was effective in protecting against carboplatin-induced hearing loss. STS delayed to 4 h after carboplatin significantly decreased time to development of ototoxicity and rate of ototoxicity when compared with HCG.

This article has been cited by other articles:

				D. R. Freyer, L. Sung, and G. H. Reaman Prevention of Hearing Loss in Children Receiving Cisplatin Chemotherapy J. Clin. Oncol., January 10, 2009; 27(2): 317 - 318. [Full Text] [PDF]

				T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, and C. P. Reynolds Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity Clin. Cancer Res., January 15, 2008; 14(2): 533 - 540. [Abstract] [Full Text] [PDF]

				K. R. G. Knight, D. F. Kraemer, and E. A. Neuwelt Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development J. Clin. Oncol., December 1, 2005; 23(34): 8588 - 8596. [Abstract] [Full Text] [PDF]

				D. T. Dickey, Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1052 - 1058. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, et al. New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting Clin. Cancer Res., January 15, 2005; 11(2): 421 - 428. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, M. A. Pagel, D. F. Kraemer, D. R. Peterson, and L. L. Muldoon Bone Marrow Chemoprotection without Compromise of Chemotherapy Efficacy in a Rat Brain Tumor Model J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 594 - 599. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, N. Ferrari, W. A. Hall, E. R. Laws, R. E. McLendon, L. L. Muldoon, D. Peereboom, D. R. Peterson, C. P. Reynolds, et al. Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium Clin. Cancer Res., June 1, 2002; 8(6): 1702 - 1709. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, M. A. Pagel, B. P. Hasler, T. G. Deloughery, and L. L. Muldoon Therapeutic Efficacy of Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model Cancer Res., November 1, 2001; 61(21): 7868 - 7874. [Abstract] [Full Text] [PDF]